Evidence map›Paper›PMID 35882974›Full record

ArticleScientific reports2022

Author Correction: Regulatory rare variants of the dopaminergic gene ANKK1 as potential risk factors for Parkinson's disease.

Estela Pérez-Santamarina, Pedro García-Ruiz, Dolores Martínez-Rubio, Mario Ezquerra, Irene Pla-Navarro, Jorge Puente, María José Martí, Francesc Palau, Janet Hoenicka

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Estela Pérez-SantamarinaCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain.
Pedro García-RuizUnit of Movement Disorders, Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain.
Dolores Martínez-RubioCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain.
Mario EzquerraLaboratory of Neurodegenerative Disorders, Department of Neurology, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain.
Irene Pla-NavarroCentro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
Jorge PuenteLabGenetics, Madrid, Spain.
María José MartíMovement Disorders Unit, Department of Neurology, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain.
Francesc Palau *Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain.
Janet Hoenicka *Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain. jhoenicka@gmail.com.
Instituto de Salud Carlos III · ESCentro de Investigacion Principe Felipe · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Clínic de Barcelona · ESHospital Universitario Fundación Jiménez Díaz · ESInstitut de Recerca Sant Joan de Déu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35882974
PMCPMC9325763
OpenAlexW4288069127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.